Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
Fort Lee, NJ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused...
Year: 2025
Cardiac Biotech Solutions, Inc. Secures Health Canada License for MyCardia AT Device, Now Branded as CardioHolter AT
LAS VEGAS, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cardiac Biotech Solutions, Inc. (OTCID: CBSC) ("CBSC" or the "Company"), a designer,...
Cosmos Health Expands Order Book with Contract Manufacturing Agreement with Medical Pharmaquality S.A. for 3 Million MYCOFAGYL® Pessaries Annually
CHICAGO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global...
ORYZON to Participate in Upcoming Events in September and October
MADRID and CAMBRIDGE, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical...
Clearmind Medicine’s Convenes Inaugural Scientific Advisory Board Meeting to Advance Psychedelic-Derived Therapies
Vancouver, Canada, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a...
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”),...
Annovis Appoints Mark Guerin as Chief Financial Officer
MALVERN, Pa., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical...
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia
MediWound Expands Global Reach with Marketing Approval of NexoBrid® in Australia TGA Approves NexoBrid® for Adults and Children; Manufacturing Readiness...
MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (Nasdaq: INKT), a clinical-stage biopharmaceutical company pioneering invariant natural...
Capricor Therapeutics Provides Regulatory Update on Deramiocel Program for Duchenne Muscular Dystrophy Following Type A Meeting
FDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support...
Kraig Biocraft Laboratories Successfully Completes First Parallel Two-Facility Production Cycle, Establishing Model for Continuous Recombinant Spider Silk Supply Chain
ANN ARBOR, Mich., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Company" or "Kraig Labs"), a...
SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery
TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage...
Evaxion out-licenses vaccine candidate EVX-B3 to MSD
MSD exercises its option on vaccine candidate EVX-B3 for a cash payment of $7.5 million, which extend Evaxion’s cash runway...
Helius Announces FDA 510(k) Submission for PoNS® Device Label Expansion in Stroke
Seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under its Breakthrough Device DesignationNEWTOWN,...
Tilray Brands, Inc. to Announce First Quarter Fiscal Year 2026 Financial Results on October 9, 2025
NEW YORK and LEAMINGTON, Ontario, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY;...
Microbix Presenting at Muskoka Capital Event
Meetings with Growth-Oriented Investors, September 26 to 28, 2025MISSISSAUGA, Ontario, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX:...
Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer’s Detection
VANCOUVER, British Columbia, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB:...
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Detailed results from completed...
RetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease Care
APOLLO BEACH, Fla., Sept. 25, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), a pioneering developmental-stage...
First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial
Enrollment remains on track with internal interim results expected in Q2 2026Randomized study to evaluate Nociscan’s ability to improve surgical...